PERSISTENT USE OF A CONTINUOUS GLUCOSE MONITORING SYSTEM OVER 12 MONTHS

Session Name
GLUCOSE SENSORS
Session Type
E-POSTER VIEWING (EXHIBITION HOURS)
Date
20.02.2020, Thursday
Session Time
09:30 - 15:30
Channel
E-Poster Area
Lecture Time
09:30 - 09:30
Presenter
  • Robert Dowd, United States of America
Authors
  • Robert Dowd, United States of America
  • Mark Derdzinski, United States of America
  • Greg Norman, United States of America
  • John Barnard Welsh, United States of America
  • Sarah Puhr, United States of America
  • Andrew Scott Parker, United States of America
  • Tomas Walker, United States of America

Abstract

Background and Aims

The benefits of continuous glucose monitoring (CGM) require ongoing use. Past studies suggest that use ≥6 days/week is optimal to obtain benefit. We examined usage of Dexcom’s G6 CGM system over the course of 12 months.

Methods

We studied anonymized data from a convenience sample of 3,000 US-based patients who first uploaded a G6 estimated glucose value (EGV) before 01-SEP-2018 and whose most recent uploaded EGV was within 1 week of the 1-year anniversary of their start date. Persistence was the percentage of observed days in which ≥1 EGV was uploaded. For each patient-week, the number of days with ≥1 EGV was calculated. Data density was the ratio of observed to possible EGVs.

Results

At 1 year, most patients had used the system on >96% of possible days and 90% of observed patient-weeks had CGM usage on ≥6 days. Overall data density was >83%. Usage statistics were high in all self-reported age groups, but lower among teens/young adults than among those <13 or >25 years of age (Table).

Age (years) <13 13-25 >25 Overall
n 500 700 1800 3000
Mean (SD) 1-year persistence 92.04 (15.61)% 87.14 (17.50)% 90.93 (14.17)% 90.22 (15.37)%
Median (IQR) 1-year persistence 98.36 (92.60-100.0)% 94.25 (82.74-98.63)% 96.71 (89.32-99.18)% 96.44 (88.49-99.18)%
Patient-weeks with ≥6 days CGM usage 90.00% 84.86% 92.00% 90.00%
Data Density 83.34% 79.71% 84.63% 83.27%

Conclusions

The high persistence, proportion of patient-weeks with ≥6 days of use, and data density suggest that G6 users trust, find value in, and benefit from their CGM.

Hide